Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Incidence of systemic infection · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Length of hospital stay · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether physiotherapy (tongue-spatula jaw exercises) changes maximal mouth opening (interincisal distance) compared with no active treatment (very low certainty).
1 finding from 1 review
Participant-reported resumption of normal eating, chewing and speech · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
MD -51.02 [-72.85, -29.20]
2 studies · 85 participants
Very low
MD -38.79 [-52.06, -25.53]
2 studies · 85 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Intolerance to spicy food (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower intolerance to spicy food (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) probably leads to lower burning sensation (VAS 0-100) compared with placebo or no active treatment (moderate certainty).
3 findings from 1 review
MD -70.82 [-94.39, -47.25]
2 studies · 500 participants
Moderate
MD -30.92 [-31.57, -30.27]
1 study · 400 participants
Moderate
MD -27.60 [-36.21, -18.99]
1 study · 90 participants
Moderate
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in maximal mouth opening (interincisal distance) compared with placebo or no active treatment (low certainty).
3 findings from 1 review
MD -1.41 [-5.74, 2.92]
1 study · 90 participants
Low
MD 3.11 [0.46, 5.77]
2 studies · 520 participants
Low
MD 8.83 [8.22, 9.45]
3 studies · 620 participants
Moderate
Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Discomfort/pain · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Difficulty in swallowing (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in swallowing (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review